Drug Search Results
Using advanced filters...
Advanced Search [+]

AZD-8108

Alternative Names: azd-8108, azd8108, azd 8108
Clinical Status: Inactive
Latest Update: 2017-04-07
Latest Update Note: Clinical Trial Update

Product Description

NMDA modulator

Mechanisms of Action: NMDA Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

AZD8108

P1

Completed

Healthy Volunteers

2015-09-01

2019-03-20

Recent News Events

Date

Type

Title